In 2006, Dr. Huang joined the Case Western Reserve University School of Medicine faculty as an Assistant Professor in the Division of Pediatric Hematology / Oncology at Rainbow Babies & Children’s Hospital - Rainbow / Seidman Cancer Center with a secondary faculty appointment in the Department of Pathology, Biomedical Engineering and General Medical Sciences, as well as a member of the Case Comprehensive Cancer Center. Currently. Dr. Huang is also the director of clinical fellowship program in Pediatric Hematology / Oncology since 2007. Dr. Huang was promoted to Associate Professor in 2012.
Our laboratory is interested in applying this and other classical immunological techniques to study various aspects of anti-tumor immune responses, immune-host-pathogen interaction, T cell-mediated memory immunity, and chemokine - receptor biology.
Ongoing projects include:
- Investigation into factors which influence the dynamic recruitment of T cells and their interactions with tumor cells and associated antigen-presenting cells in tumor-associated micro-environment.
- Imaging dynamic interaction between peri-vascular APC and T cells in the CNS during induction of acute experimental autoimmune encephalomyelitis.
- Discovering molecular signaling mechanisms responsible for the regulation of chemokine receptor expression on naive T cells.
- Testing the efficacy of genetically-modified tumor vaccines in the setting of sarcomas and other childhood cancer
- Developing imaging techniques to interrogate immune cell migration and interactions in tissues such as the bone marrow, lung, GI tract and the skin.
- Cellular and molecular mechanisms of metastasis in osteosarcoma, rhabdomyosarcoma and other common AYA and childhood cancer.
- Mechanisms of immune checkpoint regulation in solid tumors.
- Molecular mechanisms of T-cell Leukemogenesis and CNS metastasis.
- Exploring NK cell-based immunotherapy strategies against common pediatric and AYA cancers.
The long-term goal of our laboratory is to translate insights gained from basic investigations of in vivo immunity into rationally designed tumor vaccine and immunotherapeutic clinical trials, with a particular emphasis in the areas of pediatric sarcomas and other solid tumors in the pediatric and adolescent & young adult (AYA) populations.